Vimarsana
Biggest News Aggregation in the World

Page 23 - Jon Patton News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jon Patton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jon Patton Today - Breaking & Trending Today

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights - Vimarsana News

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021,...

Oncolytics Biotech Inc.: Oncolytics Biotech to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights - Vimarsana News

Oncolytics Biotech Inc.: Oncolytics Biotech to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

Conference call and webcast to take place on Friday, November 5, 2021, at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, Oct. 19, 2021 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX:

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights - Vimarsana News

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021, at...

Oncolytics Biotech Inc.: Oncolytics BiotechPartner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer - Vimarsana News

Oncolytics Biotech Inc.: Oncolytics BiotechPartner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Trial is designed to advance pelareorep's clinical development in China, the world's second-largest pharmaceutical market SAN DIEGO and CALGARY, AB, Oct. 14, 2021 /PRNewswire/ -- Oncolytics

Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer - Vimarsana News

Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has initiated dosing in a bridging clinical...